Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

BACKGROUND: Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations. METHODS: EMBRACA (NCT01945775) was a randomized phase III study comparing efficacy, safety, and patient-reported outcomes...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JNCI Cancer Spectr
Glavni autori: Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Mina, Lida A, Diab, Sami, Woodward, Natasha E, Yerushalmi, Rinat, Goodwin, Annabel, Blum, Joanne L, Martin, Miguel, Quek, Ruben G W, Tudor, Iulia Cristina, Bhattacharyya, Helen, Gauthier, Eric, Litton, Jennifer K, Eiermann, Wolfgang
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7050154/
https://ncbi.nlm.nih.gov/pubmed/32337496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkz085
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items